RecruitingHepatocellular CarcinomaGastric Cancer
Combination of TATE and PD-1 Inhibitor in Liver Cancer
Eligible age
18–80 yrs
Accepts
All genders
Locations
3 states
Healthy volunteers
No
See if you qualify for this study
Answer a few quick questions about your location and health. Takes about a minute.
About this study
This is a multi-center, open-label phase IIA study that investigates the preliminary efficacy of Trans-arterial Tirapazamine Embolization (TATE) treatment of liver cancer followed by a PD-1 checkpoint inhibitor (nivolumab). Patients with two types of cancers will be enrolled, advanced hepatocellular carcinoma (HCC),and metastatic gastric cancer. All enrolled patients need to have liver lesions and have progressed on a prior immune checkpoint inhibitor.
Sponsor: Teclison Ltd.
Where it's recruiting
Source: ClinicalTrials.gov · NCT03259867 · last updated 2026-04-16